Teva Pharmaceutical Industries Limited
$40.63B- Market cap
- $42.37B
- Debt
- +$1.82B
- Cash
- −$3.56B
Capital structure 96% equity / 4% debt · EV / Revenue 2.35x · EV / EBITDA 9.92x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TEVA stock price near parity vs PCTY $36.36 current versus $37.44 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PCTY's multiple
Implied fair value · at TEVA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TEVA FY 2025 (ended Dec 31, 2025) · PCTY FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 2.35x · EV / EBITDA 9.92x
Capital structure 99% equity / 1% debt · EV / Revenue 4.45x · EV / EBITDA 18.17x
TEVA carries the larger enterprise value at $40.63B against $7.89B; TEVA trades on the lower EV / Revenue multiple (2.35x vs 4.45x); TEVA on the lower EV / EBITDA (9.92x vs 18.17x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PAYLOCITY HOLDING CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.23x
0.07x
Net debt / EBITDA
Leverage against operating earnings
-0.42x
-0.44x
Cash and equivalents
Liquid reserves on the balance sheet
$3.56B
$271.92M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Viatris Inc
TEVA vs VTRS
Organon & Co.
TEVA vs OGN
ANI PHARMACEUTICALS INC
TEVA vs ANIP
Workday, Inc.
TEVA vs WDAY
Paycom Software, Inc.
TEVA vs PAYC
Ceridian HCM Holding Inc.
TEVA vs CDAY
PAYCHEX INC
TEVA vs PAYX
TRINET GROUP, INC.
TEVA vs TNET
AUTOMATIC DATA PROCESSING INC
TEVA vs ADP
$1.82B
$81.25M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.